{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:55:37Z","timestamp":1792788937198,"version":"4.5.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.parkreldis.2021.08.006","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T12:57:38Z","timestamp":1628600258000},"page":"79-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Impulsive conditions in Parkinson's disease: A pharmacosurveillance-supported list"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0254-2212","authenticated-orcid":false,"given":"Michele","family":"Fusaroli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0487-7996","authenticated-orcid":false,"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Contin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5939-7933","authenticated-orcid":false,"given":"Luisa","family":"Sambati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0553-539X","authenticated-orcid":false,"given":"Marco","family":"Menchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5302-0529","authenticated-orcid":false,"given":"Angelo","family":"Fioritti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7209-0426","authenticated-orcid":false,"given":"Elisabetta","family":"Poluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2021.08.006_bib1","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.neurol.2018.07.005","article-title":"Hyperdopaminergic behavioral spectrum in Parkinson's disease: a review","volume":"174","author":"B\u00e9reau","year":"2018","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.parkreldis.2021.08.006_bib2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.neurol.2018.07.009","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study in Morocco","volume":"175","author":"El Otmani","year":"2019","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.parkreldis.2021.08.006_bib3","first-page":"1","article-title":"Dopamine and reward hypersensitivity in Parkinson's disease with impulse control disorder","author":"Drew","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2021.08.006_bib4","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/mds.27689","article-title":"Scales to assess impulsive and compulsive behaviors in Parkinson's disease: critique and recommendations","volume":"34","author":"Evans","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2021.08.006_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40264-017-0590-6","article-title":"Dopamine agonists and impulse control disorders: a complex association","volume":"41","author":"Grall-Bronnec","year":"2018","journal-title":"Drug Saf."},{"key":"10.1016\/j.parkreldis.2021.08.006_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.parkreldis.2018.11.007","article-title":"Clinical pharmacokinetics of pramipexole, ropinirole and rotigotine in patients with Parkinson's disease","volume":"61","author":"Contin","year":"2019","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2021.08.006_bib7","article-title":"The social impact of suspected adverse drug reactions: an analysis of the Canada vigilance spontaneous reporting database","volume":"42","author":"Castillon","year":"2018","journal-title":"Drug Saf."},{"key":"10.1016\/j.parkreldis.2021.08.006_bib8","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.bbi.2019.06.002","article-title":"Psychosis as an adverse effect of monoclonal antibody immunotherapy","volume":"81","author":"Essali","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.parkreldis.2021.08.006_bib9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40264-016-0405-1","article-title":"Good signal detection practices: evidence from IMI PROTECT","volume":"39","author":"Wisniewski","year":"2016","journal-title":"Drug Saf."},{"key":"10.1016\/j.parkreldis.2021.08.006_bib10","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1212\/01.wnl.0000184487.72289.f0","article-title":"Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease","volume":"65","author":"Evans","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2021.08.006_bib11","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1055\/s-0037-1601887","article-title":"Impulse control disorders and related complications of Parkinson's disease therapy","volume":"37","author":"Lopez","year":"2017","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.parkreldis.2021.08.006_bib12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/wps.20115","article-title":"Impulse control disorders and \u201cbehavioural addictions\u201d in the ICD-11","volume":"13","author":"Grant","year":"2014","journal-title":"World Psychiatr."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802021002893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802021002893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:23:23Z","timestamp":1761179003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802021002893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":12,"alternative-id":["S1353802021002893"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2021.08.006","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impulsive conditions in Parkinson's disease: A pharmacosurveillance-supported list","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2021.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}